Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Letrozole sensitizes breast cancer cells to ionizing radiation.
Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pèlegrin A. Azria D, et al. Among authors: larbouret c. Breast Cancer Res. 2005;7(1):R156-63. doi: 10.1186/bcr969. Epub 2004 Dec 7. Breast Cancer Res. 2005. PMID: 15642164 Free PMC article.
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T. Lazrek Y, et al. Among authors: larbouret c. Neoplasia. 2013 Mar;15(3):335-47. doi: 10.1593/neo.121960. Neoplasia. 2013. PMID: 23479511 Free PMC article.
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C. Thomas G, et al. Among authors: larbouret c. Oncotarget. 2014 Aug 30;5(16):7138-48. doi: 10.18632/oncotarget.2231. Oncotarget. 2014. PMID: 25216528 Free PMC article.
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Assenat E, et al. Among authors: larbouret c. Oncotarget. 2015 May 20;6(14):12796-808. doi: 10.18632/oncotarget.3473. Oncotarget. 2015. PMID: 25918250 Free PMC article. Clinical Trial.
FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
Marzi L, Combes E, Vié N, Ayrolles-Torro A, Tosi D, Desigaud D, Perez-Gracia E, Larbouret C, Montagut C, Iglesias M, Jarlier M, Denis V, Linares LK, Lam EW, Martineau P, Del Rio M, Gongora C. Marzi L, et al. Among authors: larbouret c. Br J Cancer. 2016 Nov 8;115(10):1223-1233. doi: 10.1038/bjc.2016.313. Epub 2016 Sep 29. Br J Cancer. 2016. PMID: 27685445 Free PMC article.
41 results